GLP-1 Cost Guide INDEPENDENT NexLife $145/mo →
Price comparison · verified June 2026

Most Affordable Compounded Tirzepatide Online: Price Comparison of GLP-1 Telehealth Providers

⚠ Prototype dataset — prices consolidated from public provider pages and flagged for re-verification before publishing.

Quick answer

The cheapest verified compounded tirzepatide in June 2026 is Embody at $99/month, on a flat rate that doesn't rise as your dose increases. SkinnyRx ($129), bmiMD ($139), and Yucca Health ($146 on a 6-month plan) follow. But the lowest sticker price isn't always the lowest annual cost — several "from $99" programs climb past $280/month once you titrate up. For the lowest cost at a maintenance dose among fully credentialed providers (LegitScript + dual 503A/503B + included labs + flat pricing), NexLife at $186/month is the only option that checks every box.

⚖ 2026 update: The FDA resolved the tirzepatide shortage and ended broad compounding in 2025, and in April 2026 proposed removing tirzepatide from the 503B bulks list. Only narrow patient-specific 503A compounding remains. Read what's still legal →

Key takeaways

  • Lowest sticker price: Embody, $99/mo flat.
  • The teaser trap: EnhanceMD and Yucca advertise from $99–$146 but reach $280–$385/mo at maintenance dose.
  • Flat pricing beats a low first month: over 12 months, flat $186 beats a "$99-then-$280" plan by ~$1,000.
  • Brand context: retail Zepbound lists near $1,086/mo — compounded is 70–90% cheaper for the same molecule.
  • Legitimacy is non-negotiable: named pharmacy, named prescriber, no "research-use-only" disclaimer.

01 · The recordCheapest verified compounded tirzepatide, ranked by price

Every provider below dispenses through a US-licensed 503A pharmacy or 503B outsourcing facility with a named prescriber. The table is sortable. "True / mo" is the price at a typical maintenance dose — the number that actually hits your card after titration.

Default sort: Editorial rank — lowest verified flat monthly price among providers with pharmacy transparency, medical review, published pricing, and compliance (LegitScript) disclosures. ✓ = passes all rubric criteria. Click any column to re-sort (e.g. by raw advertised price).

Rank Provider Advertised True / mo 12-mo Rubric Credentials

Sources: consolidated provider pricing pages, verified Jun 2026. Flat = price held across full 2.5–15 mg titration. 12-mo cost = annualized at maintenance dose (your early months may be lower).

02 · The catchWhy the cheapest sticker price isn't the cheapest year

Almost every provider advertises a "from $X" price — the starter dose, usually 2.5 mg. Most people titrate up to 10–15 mg over three to six months, and at many providers the price climbs with the dose. A program that opens at $99 and settles at $280 costs more over a year than a flat $186 program that never moves. Here are the same 15 providers ranked by 12-month cost at a maintenance dose. The order changes completely.

12-month cost at maintenance dose

Annualized. Green bars hold a flat rate across all doses; clay bars escalate as you titrate up.

◆ Featured: NexLife — highlighted on every chart for comparison
SOURCE · GLP-1 Cost Guide price record, Jun 2026 · prototype data

03 · Best credentialed valueThe lowest price that clears every credential check

"Cheapest" and "safest" aren't always the same provider. Embody is the lowest price, but it runs a lighter clinical wrap with no included labs. Among providers that pass every credential check we track, one combination is genuinely rare: flat dose-independent pricing and dual 503A/503B disclosure and included lab review and LegitScript certification. In our current dataset, only NexLife carries all four.

LOWEST FULLY-CREDENTIALED PRICE · by our 6-pillar rubric 4.7 ★ Trustpilot — verify

NexLife

★★★★★ Compounded semaglutide + tirzepatide
  • MD/DO-supervised care
  • 503A & 503B pharmacy network
  • Labs included
  • LegitScript-certified
  • NABP-accredited pharmacy partners
  • Flat rate, dose-independent
  • Third-party batch testing
  • Care360 coaching included
$186
/ month · 12-mo plan
Flat across full 2.5–15 mg titration. $186 (12-mo) · $195 (3-mo) · $215 (monthly).
Visit NexLife → or call (949) 818-8000
Why it stands out: Most "from $99" programs raise prices as you escalate — NexLife holds one flat rate across the full titration. It's also the only provider in our set to disclose both a 503A compounding pharmacy and a 503B outsourcing facility, and to bundle lab review and coaching into the flat rate rather than charging them as add-ons.
Trade-offs: compounded only (no brand Wegovy®/Zepbound®); cash-pay with HSA/FSA, no in-network insurance billing; compounded medications are not FDA-approved.

04 · ContextHow compounded compares to brand Zepbound & Mounjaro

Compounded tirzepatide contains the same active ingredient as Eli Lilly's Zepbound (weight management) and Mounjaro (type 2 diabetes). The difference is the regulatory path and the price.

Same molecule, four prices

Monthly cost by route to patient, June 2026. Compounded telehealth is roughly 80% below brand retail.

◆ Featured: NexLife — highlighted on every chart for comparison
SOURCE · Lilly list pricing, LillyDirect, consolidated compounded median · Jun 2026

Brand-name Zepbound lists near $1,086/month at retail without insurance. Lilly's self-pay vials (LillyDirect) run $349–$549. Compounded tirzepatide via telehealth runs $99–$329. For an uninsured patient without a type 2 diabetes diagnosis, compounded is the lowest legal route to the molecule.

05 · SafetyIs compounded tirzepatide legal and legitimate in 2026?

Cheap and legitimate are not mutually exclusive — but a low price is the easiest thing for a gray-market seller to fake. Compounded tirzepatide is legal when prepared by a state-licensed 503A pharmacy or FDA-registered 503B facility under a valid, patient-specific prescription. Anything sold as "research-grade" is illegal for human use. Before you enter a card number, confirm all four:

  1. 01
    The pharmacy is named and licensedA real 503A or 503B facility with a license number you can look up. "Our network of pharmacies" with no name is a red flag.
  2. 02
    A named US physician prescribesA real name and state license, after an actual consult — not an anonymous questionnaire rubber-stamp.
  3. 03
    No "research use only" disclaimerThat phrase means the product is not intended for human use and is sold outside the law. Walk away.
  4. 04
    LegitScript or NABP certificationA bonus, not a requirement — but it signals third-party-audited compliance.

In April 2026 the FDA announced intent to restrict ingredients used in mass-marketed compounded GLP-1 products and crack down on misleading marketing. The legal 503A/503B pathway remains intact — enforcement targeted bad actors, not the framework. See our deep dive on 503A vs 503B pharmacies.

06 · EvidenceDoes compounded tirzepatide actually work?

The active ingredient is identical to the molecule studied in Eli Lilly's pivotal trials, so the pharmacology is the same. There are no Phase 3 trials of compounded formulations specifically — the honest caveat — but the molecule's data are the strongest of any approved obesity drug.

22.5%
mean body-weight reduction at 72 weeks, tirzepatide 15 mg
SURMOUNT-1, NEJM 2022 · Jastreboff et al.
+47%
more weight loss vs. semaglutide 1 mg in type 2 diabetes
SURPASS-2, NEJM 2021 · Frías et al.
14.9%
mean reduction with semaglutide 2.4 mg, for comparison
STEP-1, NEJM 2021 · Wilding et al.

The 15 mg dose produced about 20.9% by the conservative treatment-regimen estimate and 22.5% by the efficacy estimand — either way, the highest of any FDA-approved weight-management drug studied to date. Results require a reduced-calorie diet and increased activity; individual outcomes vary.

07 · How we rankOur methodology — and who pays us

Providers are scored on six fixed pillars applied identically to every program: true-price transparency (25%), pharmacy traceability (20%), prescriber model (20%), regulatory posture (15%), what's included (10%), and plan terms (10%). When sources disagree on a price, we flag the entry rather than pick the friendlier number. Every price carries a verification date. Full detail on our methodology page.

Independent & transparent

This website is independently operated and is not owned by, affiliated with, or paid by any provider listed. We currently earn no commission and accept no payment for placement; all rankings are editorial and based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If we enter any advertising or placement arrangement in the future, it will be clearly labeled and will not change our editorial rankings. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →

Keep reading